ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. Post author:admERY Post published:September 7, 2012 Post category:Newsroom You Might Also Like ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014 ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 May 24, 2022 ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 May 24, 2022
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022
